Abstract
The current study presents the design, synthesis, and evaluation of novel cytochrome P450 17A1 (CYP17A1) ligands. CYP17A1 is a key enzyme in the steroidogenic pathway that produces androgens among other steroids, and it is implicated in prostate cancer. The obtained compounds are potent enzyme inhibitors (sub µM) with antiproliferative activity in prostate cancer cell lines. The binding mode of these compounds is also discussed.
Funding Information
  • Narodowe Centrum Nauki (2019/03/X/NZ7/00900)
  • National Institutes of Health (R01 GM102505, R37 GM076343)

This publication has 38 references indexed in Scilit: